In-transit melanoma metastases: Evaluation and management for the dermatologist.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 40074149.
- Also identified by DOI 10.1016/j.jaad.2025.03.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In-transit metastases are estimated to occur in 5% to 10% of primary cutaneous melanomas. They are classified as stage III disease in the American Joint Committee on Cancer classification system and are associated with approximately a 30% 10-year survival rate. The management of in-transit metastases is not standardized. Treatment options depend on the number of lesions, location, distribution of in-transit metastases, and general medical condition of the patient. Topical, local, regional, and systemic treatment options can be considered for treatment. Dermatologists may play a unique role in management through skin-directed therapies.
Medical subject headings
- Melanoma
- Skin Neoplasms